Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.09 USD
−62.72 M USD
0.00 USD
21.31 M
About NextCure, Inc.
Sector
CEO
Michael S. Richman
Headquarters
Beltsville
Website
Founded
2015
FIGI
BBG00BTH5153
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NXTC is 1.32 USD — it has decreased by −0.76% in the past 24 hours. Watch NextCure, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NextCure, Inc. stocks are traded under the ticker NXTC.
NXTC stock has fallen by −13.33% compared to the previous week, the month change is a −5.11% fall, over the last year NextCure, Inc. has showed a 3.94% increase.
We've gathered analysts' opinions on NextCure, Inc. future price: according to them, NXTC price has a max estimate of 4.00 USD and a min estimate of 3.00 USD. Watch NXTC chart and read a more detailed NextCure, Inc. stock forecast: see what analysts think of NextCure, Inc. and suggest that you do with its stocks.
NXTC reached its all-time high on Nov 5, 2019 with the price of 109.00 USD, and its all-time low was 0.98 USD and was reached on Oct 25, 2023. View more price dynamics on NXTC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NXTC stock is 2.30% volatile and has beta coefficient of 0.73. Track NextCure, Inc. stock price on the chart and check out the list of the most volatile stocks — is NextCure, Inc. there?
Today NextCure, Inc. has the market capitalization of 36.41 M, it has decreased by −2.99% over the last week.
Yes, you can track NextCure, Inc. financials in yearly and quarterly reports right on TradingView.
NextCure, Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
NXTC earnings for the last quarter are −0.41 USD per share, whereas the estimation was −0.34 USD resulting in a −18.84% surprise. The estimated earnings for the next quarter are −0.35 USD per share. See more details about NextCure, Inc. earnings.
NextCure, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
NXTC net income for the last quarter is −11.54 M USD, while the quarter before that showed −15.40 M USD of net income which accounts for 25.08% change. Track more NextCure, Inc. financial stats to get the full picture.
No, NXTC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 82.00 employees. See our rating of the largest employees — is NextCure, Inc. on this list?
Like other stocks, NXTC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NextCure, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NextCure, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NextCure, Inc. stock shows the sell signal. See more of NextCure, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.